Showing Results for: “diabetes”

On April 4, 2025, North Dakota became the 27th state to pass a law to lower patient cost-sharing limits for insulin in state-regulated health insurance plans. In response to Governor Armstrong signing HB 1114, Matt Prokop, state government affairs director at the American Diabetes Association® (ADA), issued the following statement: “The American Diabetes Association commends North Dakota policymakers for the passage of HB 1114, which limits cost sharing for insulin and certain related supplies at $25 for a 30-day supply for those on state employee health insurance plans and state-regulated

A federal court today preliminarily approved a landmark settlement that will ensure children with diabetes in NYC receive the care they need to fully participate in school and school-related activities. This class action settlement resolves claims that New York City, the Department of Education, the Department of Health and Mental Hygiene, and the Office of School Health systemically failed to ensure that students with diabetes could attend school safely and have access to the same educational opportunities as their peers, in violation of the Americans with Disabilities Act (“ADA”), Section

Reduced hospitalization rates among people with low self-monitoring of blood glucose (SMBG) are especially pronounced People using Abbott’s FreeStyle Libre, a sensor-based glucose monitoring system, experienced a considerable decrease in ketoacidosis-related hospitalizations—52% for type 1 diabetes and 47% for type 2 diabetes—according to the study titled “Dramatic Drop in Ketoacidosis Rate after FreeStyle Libre System Initiation in Type 1 and Type 2 Diabetes in France, Especially in People with Low Self-Monitoring of Blood Glucose (SMBG): A Nationwide Study,” presented today at the American

Texas becomes 19th state to sign vital legislation to help insulin costs for those with diabetes Today, the American Diabetes Association ® (ADA) applauded a major victory secured for people with diabetes in Texas as Governor Greg Abbott signed legislation yesterday that will help make insulin more affordable for Texans on state-regulated health plans. The new law, created by Senate Bill 827 and supported by the ADA, limits cost-sharing to $25 per prescription for a 30-day supply of insulin, regardless of the amount or type of insulin needed. With the signing of this bill, Texas becomes the

First-of-Its-Kind Study Compares Open-Source Automated Insulin Delivery to Sensor-Augmented Pump Therapy Results from the CREATE Trial demonstrated open-source automated insulin delivery (AID) systems are a safe and effective therapy for people with type 1 diabetes. Findings from the randomized controlled trial (RCT) comparing open-source AID to sensor-augmented pump therapy (SAPT) were presented today at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA). Open-source AID systems were developed to reduce the burden of living with diabetes by combining an insulin pump

Medicaid and Supplemental Nutrition Assistance Program (SNAP) provide critical access to care, medications, diabetes technology and groceries for people with diabetes Deeply concerned by the proposed changes to health, hunger and nutrition programs and services advanced by the House of Representatives the American Diabetes Association® (ADA) issued the following statement. “The ADA urges the Senate to reject the harmful Medicaid and SNAP cuts proposed by the House of Representatives in H.R. 1, “One Big Beautiful Bill”, the budget reconciliation bill. We urge Congress to extend the Affordable

Data Addresses Gaps in Preventive Prescriptions Therapy, Emphasizing the Importance of Multifaceted Interventions Today, findings from the COORDINATE-Diabetes trial demonstrated that multi-disciplinary care between cardiologists, diabetes specialists and other team members can significantly increase the prescriptions of evidence-based therapies to help treat patients with both type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), commonly known as heart disease. The trial was presented as a late-breaking symposium today at the 83rd Scientific Sessions of the American

Stem Cell-Derived Fully Differentiated Islet Cells Shown to Restore Endogenous Insulin Secretion and Improved Glycemic Control in People Living with Type 1 Diabetes Today, findings from the ongoing clinical trial of VX-880, a phase 1/2, multi-center, single-arm, open-label study in patients with type 1 diabetes (T1D) were presented, demonstrating the potential of stem cell-derived islet cell therapy as a future treatment option for patients with T1D. All patients treated with VX-880 had undetectable insulin secretion and a history of recurrent severe hypoglycemic events (SHE) in the year prior

In a comparison of two different diet and two different weight management programs, results of the international PREVIEW intervention study found a low, similar rate of progression to type 2 diabetes (T2D) among people with prediabetes who had initially lost weight on a low-calorie diet (LCD), according to a symposium presentation today titled “PREVIEW Study Results—Prevention of Diabetes through Lifestyle Intervention and Population Studies Around the World” at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® in San Francisco. The study showed no difference between

New research supports monthly dosing as a next‑ generation opportunity to improve weight loss New data highlight the potential benefits of using berobenatide, an investigational injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) across patient populations—including in individuals with excess weight or obesity with or without type 2 diabetes—and dosage levels, ranging from weekly to monthly. The data were presented during symposium sessions at the 2026 Scientific Sessions of the American Diabetes Association ® (ADA) in New Orleans. Obesity and diabetes increase the risk of serious